Market news

OPKO Health eyes growth from RAYALDEE, partner revenues and a leaner BioReference, while pipeline and reimbursement risks remain key concerns.

Earlier this month, OPKO Health expanded its financing relationship with HealthCare Royalty by issuing US$125 million in senior secured notes backed by future mazdutide royalty payments from China, allowing it to raise capital without issuing new shares and with total repayments capped at 1.5 times the amount received. This royalty-backed financing structure highlights how OPKO Health is using its metabolic therapy partnerships to access non-dilutive funding while preserving potential...

On August 13, OPKO Health (NASDAQ:OPK) expanded its financing relationship with HealthCare Royalty, a business of KKR, issuing an additional $125 million in senior secured notes secured by the royalty stream tied to mazdutide, the GLP-1 drug OPKO licensed to Eli Lilly and now collects royalties on in China. The notes mature in 2044, matching […]

OPKO Health (NASDAQ:OPK) outlined a strategy to shift its business mix toward therapeutics while continuing to streamline its diagnostics operations, with management highlighting a pipeline of early-stage clinical programs, external collaborations and capital available to fund development. Speaking

OPKO Health (OPK) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

OPKO Health's growth outlook is supported by RAYALDEE, strategic partnerships, BioReference restructuring and multiple pipeline catalysts.

By David Bautz, PhD NASDAQ: COCP READ THE FULL COCP RESEARCH REPORT Business Update CDI-988 Approaches Key Readout Cocrystal Pharma, Inc. (NASDAQ: COCP) is continuing its Phase 1b human challenge study of CDI-988 to evaluate its potential as a prevention and treatment of norovirus infection. We anticipate topline data before the end of 2026. CDI-988 is an oral, direct-acting antiviral designed to

OPKO Health secured $125 million in royalty-backed financing, adding non-dilutive capital while retaining long-term exposure to mazdutide growth in China.

OPKO Health pairs a discounted forward sales multiple with narrowing losses and partnership support, but early-stage clinical risk keeps the investment case balanced.

OPKO Health's 12.4% monthly gain is backed by narrower losses and better margins, though profitability and clinical execution remain key risks.

OPK raises $125 million against mazdutide royalties, gaining non-dilutive capital while retaining longer-term royalty upside.

Transaction provides additional non-dilutive capital and enhanced financial flexibility while preserving meaningful long-term royalty upsideMIAMI, Fla., Aug. 13, 2026 (GLOBE NEWSWIRE) -- OPKO Health, Inc. (NASDAQ: OPK) today announced the expansion of its financing relationship with HealthCare Royalty, a business of KKR (HCRx), through the issuance of an additional $125 million aggregate principal amount of senior secured notes. The newly issued notes are secured by OPKO’s royalty interests aris

OPKO Health (OPK) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

Longtime investor OPKO Health increases its position as Cocrystal advances toward norovirus Phase 1b data in late 2026 BOTHELL, Wash., Aug. 03, 2026 (GLOBE NEWSWIRE) -- Cocrystal Pharma, Inc. (Nasdaq: COCP) ("Cocrystal" or the "Company"), a biotechnology company developing novel antiviral therapeutics, today announced a $5 million investment from OPKO Health, Inc. (Nasdaq: OPK) (“OPKO”), a longtime investor in the Company, has increased its position through a $5 million investment as the Company

Detailed price information for Opko Health Inc (OPK-Q) from The Globe and Mail including charting and trades.

Detailed price information for Opko Health Inc (OPK-Q) from The Globe and Mail including charting and trades.

Detailed price information for Opko Health Inc (OPK-Q) from The Globe and Mail including charting and trades.

Detailed price information for Opko Health Inc (OPK-Q) from The Globe and Mail including charting and trades.

Detailed price information for Opko Health Inc (OPK-Q) from The Globe and Mail including charting and trades.

Gainers OPKO Health (NASDAQ:OPK) shares increased by 34.7% to $1.67 during Tuesday's regular session. The company's market cap stands at $936.3 million. As per the press release, Q2 earnings came out yesterday.

US stocks trade higher, Dow up 1% on Tuesday. Boeing gains 5% after reporting Q2 results. Kiniksa Pharma, OPKO Health, Itron, up over 20%.

OPK beats Q2 estimates as pharmaceutical growth, Nicoya income and lower costs narrow losses and lift shares pre-market.

OPKO Health Inc (OPK) reports significant revenue growth in pharmaceuticals and a notable reduction in net loss, despite challenges in diagnostics.

It posted a beat-and-raise second quarter.

OPKO Health, Inc. reported its second-quarter 2026 results on July 27, 2026, with revenue of US$163.58 million and a net loss of US$8.42 million, alongside updated guidance calling for total revenue of US$131 million to US$142 million for the third quarter and US$560 million to US$585 million for full-year 2026. The sharp reduction in quarterly net loss compared with a year earlier, despite mixed revenue trends over the first half, gives investors more detail on how OPKO’s cost structure and...

Moby summary of OPKO Health, Inc.'s Q2 2026 earnings call

While the top- and bottom-line numbers for OPKO Health (OPK) give a sense of how the business performed in the quarter ended June 2026, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.

OPKO Health (OPK) delivered earnings and revenue surprises of +87.50% and +24.68%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?

At Yahoo Finance, you get free stock quotes, up-to-date news, portfolio management resources, international market data, social interaction and mortgage rates that help you manage your financial life.

Conference Call to Begin Today at 4:30 p.m. ETMIAMI, July 27, 2026 (GLOBE NEWSWIRE) -- OPKO Health, Inc. (OPKO) (NASDAQ: OPK), a fully-integrated healthcare company focused on delivering next-generation solutions for serious diseases across established global markets, today reports business highlights and financial results for the second quarter ended June 30, 2026. Highlights from the second quarter of 2026 and recent weeks included the following: ModeX presented data on multispecific antibody

OPKO Health (OPK) reported a Q2 loss late Monday of $0.01 per diluted share, narrowing from the loss

OPKO Health's growth outlook rests on RAYALDEE, BioReference gains and partnerships, though losses and pipeline risks persist.

MIAMI, July 23, 2026 (GLOBE NEWSWIRE) -- OPKO Health, Inc. (OPKO) (NASDAQ: OPK), a fully-integrated healthcare company focused on delivering next-generation solutions for serious diseases across established global markets, today announced that it will report operating and financial results for the second-quarter 2026 on Monday, July 27, 2026. OPKO’s senior management will host a conference call and webcast at 4:30 p.m. ET to provide a business update, discuss results and financial guidance. CONF